blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3893893

EP3893893 - METHODS FOR IMPROVING EXERCISE TOLERANCE IN MYALGIC ENCEPHALOMYELITIS PATIENTS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  17.09.2021
Database last updated on 14.09.2024
FormerThe international publication has been made
Status updated on  20.06.2020
Formerunknown
Status updated on  06.01.2020
Most recent event   Tooltip24.10.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
AIM ImmunoTech Inc.
2117 SW Highway 484
Ocala, FL 34473 / US
[2023/26]
Former [2021/42]For all designated states
Aim Immunotech Inc.
2117 SW Highway 484
Ocala FL 34473 / US
Inventor(s)01 / STRAYER, David, R.
c/o AIM Immunotech Inc. 2117 SW Highway 484
Ocala, FL 34473 / US
02 / YOUNG, Diane, L.
c/o AIM Immunotech Inc. 2117 SW Highway 484
Ocala, FL 34473 / US
03 / EQUELS, Thomas, K.
c/o AIM Immunotech Inc. 2117 SW Highway 484
Ocala, FL 34473 / US
 [2021/42]
Representative(s)V.O.
P.O. Box 87930
2508 DH Den Haag / NL
[2021/42]
Application number, filing date19827888.925.11.2019
[2021/42]
WO2019US63048
Priority number, dateUS201862778935P13.12.2018         Original published format: US 201862778935 P
[2021/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020123136
Date:18.06.2020
Language:EN
[2020/25]
Type: A1 Application with search report 
No.:EP3893893
Date:20.10.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 18.06.2020 takes the place of the publication of the European patent application.
[2021/42]
Search report(s)International search report - published on:EP18.06.2020
ClassificationIPC:A61K31/713, A61P25/00
[2021/42]
CPC:
A61K31/713 (EP,KR,US); A61K47/61 (KR,US); A61K47/645 (KR,US);
A61P21/06 (US); A61P25/00 (EP,KR); G01N33/48 (EP);
Y02A50/30 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/42]
TitleGerman:VERFAHREN ZUR VERBESSERUNG DER TRAININGSTOLERANZ BEI PATIENTEN MIT ENCEPHALOMYELITIS[2021/42]
English:METHODS FOR IMPROVING EXERCISE TOLERANCE IN MYALGIC ENCEPHALOMYELITIS PATIENTS[2021/42]
French:MÉTHODES POUR AMÉLIORER LA TOLÉRANCE À L'EFFORT CHEZ DES PATIENTS ATTEINTS D'UNE ENCÉPHALOMYÉLITE MYALGIQUE[2021/42]
Entry into regional phase01.07.2021National basic fee paid 
01.07.2021Designation fee(s) paid 
01.07.2021Examination fee paid 
Examination procedure01.07.2021Amendment by applicant (claims and/or description)
01.07.2021Examination requested  [2021/42]
01.07.2021Date on which the examining division has become responsible
Fees paidRenewal fee
23.11.2021Renewal fee patent year 03
21.11.2022Renewal fee patent year 04
24.10.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[I]WO2010042229  (HEMISPHERX BIOPHARMA INC [US], et al) [I] 1-16 * the whole document *;
 [I]WO2010104571  (HEMISPHERX BIOPHARMA INC [US], et al) [I] 1-16* the whole document *;
 [I]WO2015010022  (HEMISPHERX BIOPHARMA INC [US]) [I] 1-16 * the whole document *;
 [I]  - WILLIAM M MITCHELL, "Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)", EXPERT REVIEW OF CLINICAL PHARMACOLOGY 20141101 EXPERT REVIEWS LTD. GBR, UK, (20160525), vol. 9, no. 6, doi:10.1586/17512433.2016.1172960, ISSN 1751-2433, pages 755 - 770, XP055556867 [I] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1586/17512433.2016.1172960
by applicantUS4024222
 US4130641
 US5258369
 US8722874
 US9315538
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.